The chromatin immunoprecipitation (ChIP) assay data showed that doxorubicin treatment promoted the binding of HP1γ to the promoter region of UBE2L3 gene in cervical cancer cells (Figure 5B–D). The gene discussed is UBE2L3; the disease is cervical cancer.